A Single-Dose Safety and Tolerability Placebo Controlled Study of Subcutaneous SCH 900222 in Healthy Volunteers

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000233224

Enrollment

Registered

2009-05-08

Start date

2009-06-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study will evaluate the safety, tolerability, & pharmacokinetic response to SCH 900222 subcutaneous fixed dose in healthy subjects.

Interventions

A single dose of either 50mg or 200mg SCH 900222 administered as a subcutaneous single injection.

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

-Male/Female Healthy volunteers must have no history of latent or active tuberculosis (TB) prior to screening

Exclusion criteria

History of malignancy, Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C, active or latent mycobacterium tuberculosis

Outcome results